

# Intertumoral Heterogeneity within Medulloblastoma S

Cancer Cell

31, 737-754.e6

DOI: [10.1016/j.ccell.2017.05.005](https://doi.org/10.1016/j.ccell.2017.05.005)

Citation Report

#	ARTICLE	IF	CITATIONS
1	From One to Many: Further Refinement of Medulloblastoma Subtypes Offers Promise for Personalized Therapy. <i>Cancer Cell</i> , 2017, 31, 727-729.	7.7	11
2	Challenges and Recent Advances in Medulloblastoma Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1061-1084.	4.0	66
3	An enhanced deterministic K-Means clustering algorithm for cancer subtype prediction from gene expression data. <i>Computers in Biology and Medicine</i> , 2017, 91, 213-221.	3.9	80
4	Oncogenic role of cytomegalovirus in medulloblastoma?. <i>Cancer Letters</i> , 2017, 408, 55-59.	3.2	9
5	Put away your microscopes: the ependymoma molecular era has begun. <i>Current Opinion in Oncology</i> , 2017, 29, 443-447.	1.1	21
6	Medulloblastoma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 134, 679-689.	3.9	25
7	Distinctive localization and MRI features correlate of molecular subgroups in adult medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 353-360.	1.4	23
8	Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. <i>Cell Reports</i> , 2017, 21, 2772-2784.	2.9	31
9	EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10532-E10539.	3.3	104
12	Obstacles to Brain Tumor Therapy: Key ABC Transporters. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2544.	1.8	67
13	Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma. <i>Oncotarget</i> , 2017, 8, 78978-78988.	0.8	4
14	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. <i>Oncogene</i> , 2018, 37, 2850-2862.	2.6	71
15	Characterization of a novel OTX-driven stem cell program in Group 3 and Group 4 medulloblastoma. <i>Molecular Oncology</i> , 2018, 12, 495-513.	2.1	16
16	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF- $\beta$ -OTX2-SNAIL via PTEN inhibition. <i>Brain</i> , 2018, 141, 1300-1319.	3.7	22
17	Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis. <i>Journal of Neuro-Oncology</i> , 2018, 139, 333-340.	1.4	9
18	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. <i>Annual Review of Neuroscience</i> , 2018, 41, 207-232.	5.0	85
20	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	3.9	17
21	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	3.2	24

#	ARTICLE	IF	CITATIONS
22	Epigenetic regulation in medulloblastoma. <i>Molecular and Cellular Neurosciences</i> , 2018, 87, 65-76.	1.0	22
23	Desmoplastic nodular medulloblastoma in young children: a management dilemma. <i>Neuro-Oncology</i> , 2018, 20, 1026-1033.	0.6	8
24	Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. <i>Child's Nervous System</i> , 2018, 34, 809-815.	0.6	20
25	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313.	3.9	20
26	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. <i>Cell Reports</i> , 2018, 22, 3206-3216.	2.9	19
27	MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. <i>American Journal of Neuroradiology</i> , 2018, 39, 949-955.	1.2	27
28	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. <i>Cancer Cell</i> , 2018, 33, 435-449.e6.	7.7	52
29	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3392-3397.	3.3	34
30	Taxonomy of <sc>CNS</sc> tumours; a series of three short reviews on the <sc>WHO</sc> 2016 classification and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 137-138.	1.8	4
31	<sc>CNS</sc> embryonal tumours: <sc>WHO</sc> 2016 and beyond. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 151-162.	1.8	33
32	Epigenetic Drivers in Pediatric Medulloblastoma. <i>Cerebellum</i> , 2018, 17, 28-36.	1.4	59
33	Differential patterns of metastatic dissemination across medulloblastoma subgroups. <i>Journal of Neurosurgery: Pediatrics</i> , 2018, 21, 145-152.	0.8	39
34	From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 83-105.	2.7	67
35	Review of molecular classification and treatment implications of pediatric brain tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 3-9.	1.0	38
36	Precision Medicine in Pediatric Neurooncology: A Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 11-28.	1.7	12
37	BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. <i>Database: the Journal of Biological Databases and Curation</i> , 2018, 2018, .	1.4	17
38	Are molecular subgroups of medulloblastomas really prognostic?. <i>Current Opinion in Neurology</i> , 2018, 31, 747-751.	1.8	2
39	Decoding Somatic Driver Gene Mutations and Affected Signaling Pathways in Human Medulloblastoma Subgroups. <i>Journal of Cancer</i> , 2018, 9, 4596-4610.	1.2	13

#	ARTICLE	IF	CITATIONS
40	Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 189, 298-305.	1.7	16
41	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. <i>Radiographics</i> , 2018, 38, 2102-2122.	1.4	75
42	Interrogating molecular data for medulloblastoma risk stratification. <i>Lancet Oncology</i> , The, 2018, 19, 1548-1549.	5.1	3
43	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1602-1616.	5.1	67
44	A functional genomics approach to identify pathways of drug resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 146.	2.4	10
45	Malignant Brain Tumours in Children : Present and Future Perspectives. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 402-406.	0.5	3
46	Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 376-385.	0.5	2
47	Childhood Medulloblastoma Revisited. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 479-502.	0.7	10
48	Low Expression of miR-466f-3p Sustains Epithelial to Mesenchymal Transition in Sonic Hedgehog Medulloblastoma Stem Cells Through Vegfa-Nrp2 Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 1281.	1.6	20
50	Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule. <i>Cell Death Discovery</i> , 2018, 4, 41.	2.0	30
51	Pharmacological inhibition of LSD1 activity blocks REST-dependent medulloblastoma cell migration. <i>Cell Communication and Signaling</i> , 2018, 16, 60.	2.7	23
52	DNA polymerase $\beta$ deficiency in the p53 null cerebellum leads to medulloblastoma formation. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 548-553.	1.0	6
53	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , 2018, 124, 4168-4180.	2.0	64
54	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. <i>Nature Communications</i> , 2018, 9, 4121.	5.8	36
55	Molecular characterization of Wnt pathway and function of $\beta$ -catenin overexpression in medulloblastoma cell lines. <i>Cytotechnology</i> , 2018, 70, 1713-1722.	0.7	11
56	Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	54
57	The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer. <i>Biomolecules</i> , 2018, 8, 112.	1.8	6
58	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 85.	1.3	9

#	ARTICLE	IF	CITATIONS
59	A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression. <i>Neuron</i> , 2018, 100, 799-815.e7.	3.8	241
60	Loss of AMPK $\pm$ 2 Impairs Hedgehog-Driven Medulloblastoma Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3287.	1.8	5
61	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. <i>Cancer Cell</i> , 2018, 34, 379-395.e7.	7.7	104
62	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2018, 34, 396-410.e8.	7.7	146
63	Multiomic Medulloblastomas. <i>Cancer Cell</i> , 2018, 34, 351-353.	7.7	5
65	New stratification for early childhood medulloblastoma. <i>Pediatric Medicine</i> , 2018, 1, 10-10.	1.1	2
66	Subgroup-specific immune and stromal microenvironment in medulloblastoma. <i>Oncolmmunology</i> , 2018, 7, e1462430.	2.1	77
67	The clinical importance of medulloblastoma extent of resection: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 139, 523-539.	1.4	43
68	The developmental origin of brain tumours: a cellular and molecular framework. <i>Development (Cambridge)</i> , 2018, 145, .	1.2	97
69	Medulloblastoma in infants: the never-ending challenge. <i>Lancet Oncology, The</i> , 2018, 19, 720-721.	5.1	7
70	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2018, 19, 768-784.	5.1	151
71	MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641877537.	1.5	28
72	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. <i>Scientific Reports</i> , 2018, 8, 8733.	1.6	17
73	TGF- $\beta$ 2 Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. <i>Cell Reports</i> , 2018, 23, 3798-3812.e8.	2.9	33
74	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. <i>Cancer Research</i> , 2018, 78, 4745-4759.	0.4	31
75	MicroRNA&ndash;mRNA expression profiles associated with medulloblastoma subgroup 4. <i>Cancer Management and Research</i> , 2018, Volume 10, 339-352.	0.9	11
76	Clinical and pre-clinical utility of genomics in medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 633-647.	1.4	13
77	Targeting mTOR as a Therapeutic Approach in Medulloblastoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1838.	1.8	13

#	ARTICLE	IF	CITATIONS
78	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. <i>Acta Neuropathologica Communications</i> , 2018, 6, 48.	2.4	35
79	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
80	Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 12, 490-503.	2.3	36
81	Infant medulloblastoma "learning new lessons from old strata. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 659-660.	12.5	15
82	New insights from the widening homogeneity perspective to target intratumor heterogeneity. <i>Cancer Communications</i> , 2018, 38, 1-7.	3.7	9
83	Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma. <i>Neoplasia</i> , 2018, 20, 965-974.	2.3	32
84	Sonic Hedgehog Medulloblastoma Cancer Stem Cells Mirnome and Transcriptome Highlight Novel Functional Networks. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2326.	1.8	14
85	Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 11807.	1.6	43
86	Clinical Applications of Quantitative 3-Dimensional MRI Analysis for Pediatric Embryonal Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 744-756.	0.4	10
87	Patient Similarity Networks for Precision Medicine. <i>Journal of Molecular Biology</i> , 2018, 430, 2924-2938.	2.0	93
88	Epigenetic cerebellar diseases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 227-244.	1.0	18
89	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. <i>Cancer Cell</i> , 2018, 33, 1004-1016.e5.	7.7	52
90	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 696-702.	0.9	38
91	Inactivation of Citron Kinase Inhibits Medulloblastoma Progression by Inducing Apoptosis and Cell Senescence. <i>Cancer Research</i> , 2018, 78, 4599-4612.	0.4	24
92	Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. <i>Oncogene</i> , 2019, 38, 6867-6879.	2.6	18
93	Integrative analysis of gene expression and DNA methylation through one-class logistic regression machine learning identifies stemness features in medulloblastoma. <i>Molecular Oncology</i> , 2019, 13, 2227-2245.	2.1	93
94	RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression. <i>BMC Bioinformatics</i> , 2019, 20, 428.	1.2	36
95	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98

#	ARTICLE	IF	CITATIONS
96	Clinical Utility of GliSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 694-702.	0.9	3
97	Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 698.	1.6	15
98	Surgical resection of medulloblastoma: How much is sufficient and necessary? A systematic review of literature. <i>Cancer Reports</i> , 2019, 2, .	0.6	0
99	An autocrine ActivinB mechanism drives $\text{TGF}\beta^2$ /Activin signaling in Group 3 medulloblastoma. <i>EMBO Molecular Medicine</i> , 2019, 11, e9830.	3.3	13
100	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	13.7	273
101	Biological characterization of the UW402, UW473, ONS-76 and DAOY pediatric medulloblastoma cell lines. <i>Cytotechnology</i> , 2019, 71, 893-903.	0.7	8
102	Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 123.	2.4	73
103	Leukotriene Synthesis Is Critical for Medulloblastoma Progression. <i>Clinical Cancer Research</i> , 2019, 25, 6475-6486.	3.2	10
104	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. <i>Journal of Neuro-Oncology</i> , 2019, 145, 375-383.	1.4	7
105	Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz027.	0.4	5
106	KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2. <i>Oncogenesis</i> , 2019, 8, 64.	2.1	21
107	Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma. <i>BMC Cancer</i> , 2019, 19, 1056.	1.1	22
108	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	1.2	9
109	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020, 22, 290-297.	0.6	21
110	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. <i>Journal of Neuro-Oncology</i> , 2019, 145, 107-114.	1.4	18
111	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. <i>Cancer Cell</i> , 2019, 36, 302-318.e7.	7.7	96
112	Looking beyond the hype: Applied AI and machine learning in translational medicine. <i>EBioMedicine</i> , 2019, 47, 607-615.	2.7	82
113	Medulloblastoma rendered susceptible to NK-cell attack by $\text{TGF}\beta^2$ neutralization. <i>Journal of Translational Medicine</i> , 2019, 17, 321.	1.8	32

#	ARTICLE	IF	CITATIONS
114	The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway. <i>Cell Death and Disease</i> , 2019, 10, 715.	2.7	17
115	High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. <i>Cell Death and Disease</i> , 2019, 10, 696.	2.7	27
116	Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. <i>Scientific Reports</i> , 2019, 9, 13611.	1.6	19
117	Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma. <i>Science Signaling</i> , 2019, 12, .	1.6	19
118	SUFU: The Jekyll and Hyde of the Cerebellum. <i>Developmental Cell</i> , 2019, 48, 131-132.	3.1	1
119	Molecular genetics of medulloblastoma in children: diagnostic, therapeutic and prognostic implications. <i>Future Neurology</i> , 2019, 14, FNL8.	0.9	18
120	&lt;p&gt;Medulloblastoma: optimizing care with a multidisciplinary approach&lt;/p&gt;. <i>Journal of Multidisciplinary Healthcare</i> , 2019, Volume 12, 335-347.	1.1	47
121	Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 990-1005.	1.7	17
122	Expanding the clinical history associated with syndromic Klippel-Feil: A unique case of comorbidity with medulloblastoma. <i>European Journal of Medical Genetics</i> , 2019, 62, 103701.	0.7	12
123	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	5.2	56
124	Updates on Management of Adult Medulloblastoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 64.	1.3	44
126	Molecular pathology of tumors of the central nervous system. <i>Annals of Oncology</i> , 2019, 30, 1265-1278.	0.6	129
127	Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage. <i>Neurosurgery</i> , 2020, 86, 478-484.	0.6	2
128	Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2410.	5.8	99
129	Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. <i>BMC Cancer</i> , 2019, 19, 571.	1.1	40
130	A novel finding of an IDH2 mutation in an interesting adult Sonic Hedgehog mutated medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 231-233.	1.4	4
131	Human Sialic acid O-acetyl esterase (SIAE)-mediated changes in sensitivity to etoposide in a medulloblastoma cell line. <i>Scientific Reports</i> , 2019, 9, 8609.	1.6	10
132	A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1150-1163.	0.6	24



#	ARTICLE	IF	CITATIONS
133	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	3.9	180
134	The long noncoding RNA <i>TP73AS1</i> promotes tumorigenicity of medulloblastoma cells. <i>International Journal of Cancer</i> , 2019, 145, 3402-3413.	2.3	27
135	Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres. <i>Journal of Neuro-Oncology</i> , 2019, 143, 393-403.	1.4	16
136	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	13.7	293
137	Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. <i>Clinical Science</i> , 2019, 133, 953-970.	1.8	79
138	5-ALA fluorescence-guided surgery in pediatric brain tumors—a systematic review. <i>Acta Neurochirurgica</i> , 2019, 161, 1099-1108.	0.9	43
139	Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. <i>Journal of Hematology and Oncology</i> , 2019, 12, 29.	6.9	41
140	Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales. <i>Cancer Research</i> , 2019, 79, 2426-2434.	0.4	31
141	A simplified approach using Taqman low-density array for medulloblastoma subgrouping. <i>Acta Neuropathologica Communications</i> , 2019, 7, 33.	2.4	18
142	TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma. <i>Acta Neuropathologica</i> , 2019, 137, 657-673.	3.9	20
143	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. <i>Journal of Neuro-Oncology</i> , 2019, 142, 435-444.	1.4	14
144	Effective and safe tumor inhibition using vinblastine in medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27694.	0.8	7
145	Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma. <i>Cells</i> , 2019, 8, 216.	1.8	4
146	<i>MYC</i> Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells. <i>Cancer Research</i> , 2019, 79, 1967-1980.	0.4	29
147	Long Noncoding RNAs: Emerging Players in Medulloblastoma. <i>Frontiers in Pediatrics</i> , 2019, 7, 67.	0.9	8
148	Developmental origins and oncogenic pathways in malignant brain tumors. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2019, 8, e342.	5.9	35
149	Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells. <i>BMC Cancer</i> , 2019, 19, 300.	1.1	11
150	Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 52.	2.4	17

#	ARTICLE	IF	CITATIONS
151	Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI. <i>Journal of Neuro-Oncology</i> , 2019, 142, 395-407.	1.4	25
152	Modulating native GABAA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death. <i>Journal of Neuro-Oncology</i> , 2019, 142, 411-422.	1.4	18
153	Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. <i>Bioinformatics</i> , 2019, 35, 3357-3364.	1.8	34
154	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	3.9	9
155	Inhibition of the amino acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2711-2718.	1.6	34
156	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
157	Medulloblastoma in the age of molecular subgroups: a review. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 24, 353-363.	0.8	153
158	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. <i>Nature Communications</i> , 2019, 10, 5829.	5.8	77
159	CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 612-629.	0.9	8
160	EANO – EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	5.1	56
161	Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. <i>Cell Stem Cell</i> , 2019, 25, 855-870.e11.	5.2	38
162	The therapeutic and diagnostic potential of regulatory noncoding RNAs in medulloblastoma. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz023.	0.4	16
163	Aberrantly expressed microRNAs and their implications in childhood central nervous system tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 813-828.	2.7	10
164	Pediatric Patients With SHH Medulloblastoma Fail Differently as Compared With Adults: Possible Implications for Treatment Modifications. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e499-e505.	0.3	7
165	Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma. <i>Cancers</i> , 2019, 11, 1985.	1.7	12
166	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	13.7	129
167	Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 683-694.	2.7	22
168	Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma. <i>Developmental Cell</i> , 2019, 48, 167-183.e5.	3.1	39

#	ARTICLE	IF	CITATIONS
169	Medulloblastoma: Challenges and advances in treatment and research. <i>Cancer Reports</i> , 2019, 2, .	0.6	4
170	Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high- $\alpha$ MYC medulloblastoma. <i>Neuropathology</i> , 2019, 39, 71-77.	0.7	8
171	BMI1 is a therapeutic target in recurrent medulloblastoma. <i>Oncogene</i> , 2019, 38, 1702-1716.	2.6	20
172	Establishment and Culture of Patient-Derived Primary Medulloblastoma Cell Lines. <i>Methods in Molecular Biology</i> , 2019, 1869, 23-36.	0.4	4
173	Bioinformatic Strategies for the Genomic and Epigenomic Characterization of Brain Tumors. <i>Methods in Molecular Biology</i> , 2019, 1869, 37-56.	0.4	4
174	MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2019, 40, 154-161.	1.2	87
175	Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors. <i>Brain Tumor Pathology</i> , 2019, 36, 1-6.	1.1	6
176	Targeted Therapies for Pediatric Central Nervous System Tumors. , 2019, , 375-382.		0
177	Granule neuron precursor cell proliferation is regulated by NFIX and intersectin 1 during postnatal cerebellar development. <i>Brain Structure and Function</i> , 2019, 224, 811-827.	1.2	10
178	A CK1 $\beta$ Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 1379-1388.	3.2	20
179	Machine learning for integrating data in biology and medicine: Principles, practice, and opportunities. <i>Information Fusion</i> , 2019, 50, 71-91.	11.7	340
180	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. <i>Neuro-Oncology</i> , 2019, 21, 214-221.	0.6	31
181	Nuclear Factor One X in Development and Disease. <i>Trends in Cell Biology</i> , 2019, 29, 20-30.	3.6	36
182	CTGF expression is indicative of better survival rates in patients with medulloblastoma. <i>Cancer Gene Therapy</i> , 2020, 27, 378-382.	2.2	4
183	Genetics of Common Pediatric Brain Tumors. <i>Pediatric Neurology</i> , 2020, 104, 3-12.	1.0	14
184	Texture Analysis of T1-Weighted Contrast-Enhanced Magnetic Resonance Imaging Potentially Predicts Outcomes of Patients with Non-Wingless-Type/Non-Sonic Hedgehog Medulloblastoma. <i>World Neurosurgery</i> , 2020, 137, e27-e33.	0.7	4
185	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	0.8	50
186	MEMRI-based imaging pipeline for guiding preclinical studies in mouse models of sporadic medulloblastoma. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 214-227.	1.9	4

#	ARTICLE	IF	CITATIONS
187	Proteome and miRNome profiling of microvesicles derived from medulloblastoma cell lines with stem-like properties reveals biomarkers of poor prognosis. <i>Brain Research</i> , 2020, 1730, 146646.	1.1	19
188	Pediatric embryonal brain tumors in the molecular era. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 293-303.	1.5	6
189	The molecular biology of medulloblastoma metastasis. <i>Brain Pathology</i> , 2020, 30, 691-702.	2.1	25
190	B7 <sup>H3</sup> as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. <i>Translational Oncology</i> , 2020, 13, 365-371.	1.7	33
191	Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 538-543.	0.6	13
192	A Hierarchical Clustering algorithm based on Silhouette Index for cancer subtype discovery from genomic data. <i>Neural Computing and Applications</i> , 2020, 32, 11459-11476.	3.2	17
193	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	12.8	147
194	Sonic Hedgehog <sup>+</sup> Activated Large Cell/Anaplastic Medulloblastoma with Myogenic Differentiation. <i>World Neurosurgery</i> , 2020, 135, 16-18.	0.7	2
195	Modeling pediatric medulloblastoma. <i>Brain Pathology</i> , 2020, 30, 703-712.	2.1	28
196	Medulloblastoma genomics in the modern molecular era. <i>Brain Pathology</i> , 2020, 30, 679-690.	2.1	39
197	Biallelic PTCH1 Inactivation Is a Dominant Genomic Change in Sporadic Keratocystic Odontogenic Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 553-560.	2.1	20
198	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children <sup>TM</sup> s Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	0.8	40
199	Pediatric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 143-159.	0.9	6
200	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	3.9	13
201	Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth. <i>Cancers</i> , 2020, 12, 73.	1.7	10
202	Molecular subgrouping of atypical teratoid/rhabdoid tumors <sup>TM</sup> a reinvestigation and current consensus. <i>Neuro-Oncology</i> , 2020, 22, 613-624.	0.6	133
203	Epigenetic pathways and plasticity in brain tumors. <i>Neurobiology of Disease</i> , 2020, 145, 105060.	2.1	15
204	VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. <i>Communications Biology</i> , 2020, 3, 579.	2.0	9

#	ARTICLE	IF	CITATIONS
205	A circular RNA from NFIX facilitates oxidative stress-induced H9c2 cells apoptosis. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2020, 56, 715-722.	0.7	11
206	Embryonal tumors of the central nervous system. <i>Current Opinion in Oncology</i> , 2020, 32, 623-630.	1.1	5
207	The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1159-1181.	1.5	33
208	Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma. <i>Frontiers in Genetics</i> , 2020, 11, 563882.	1.1	8
209	Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. <i>Science Advances</i> , 2020, 6, .	4.7	42
210	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. <i>Cancer Research</i> , 2020, 80, 5393-5407.	0.4	38
211	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. <i>Nature Communications</i> , 2020, 11, 3627.	5.8	21
212	<i>Pediatric Chemotherapy</i> , 2020, , 173-183.		0
213	Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 599253.	2.2	11
214	Gene Expression Signatures Identify Biologically Homogenous Subgroups of Grade 2 Meningiomas. <i>Frontiers in Oncology</i> , 2020, 10, 541928.	1.3	4
215	Advances in Targeted Therapies for Pediatric Brain Tumors. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	16
216	Histopathologic and Molecular Features of Central Nervous System Embryonal Tumors for Integrated Diagnosis Reporting. <i>Surgical Pathology Clinics</i> , 2020, 13, 783-800.	0.7	1
217	Medulloblastoma: "Onset of the molecular era". <i>Molecular Biology Reports</i> , 2020, 47, 9931-9937.	1.0	6
218	Extracellular vesicle-associated miR-135b and -135a regulate stemness in Group 4 medulloblastoma cells by targeting angiotenin-like 2. <i>Cancer Cell International</i> , 2020, 20, 558.	1.8	9
219	Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma. <i>Cell Death and Disease</i> , 2020, 11, 1035.	2.7	28
220	Clinical and mutational profiles of adult medulloblastoma groups. <i>Acta Neuropathologica Communications</i> , 2020, 8, 191.	2.4	30
221	A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology. <i>Acta Neuropathologica Communications</i> , 2020, 8, 124.	2.4	18
222	Sonic hedgehog accelerates DNA replication to cause replication stress promoting cancer initiation in medulloblastoma. <i>Nature Cancer</i> , 2020, 1, 840-854.	5.7	16

#	ARTICLE	IF	CITATIONS
223	Should we keep rocking? Portraits from targeting Rho kinases in cancer. <i>Pharmacological Research</i> , 2020, 160, 105093.	3.1	19
224	Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20127-20138.	3.3	23
225	The Illumina Infinium methylation assay for genome-wide methylation analyses. , 2020, , 117-140.		2
226	Real-time sensing of MAPK signaling in medulloblastoma cells reveals cellular evasion mechanism counteracting dasatinib blockade of ERK activation during invasion. <i>Neoplasia</i> , 2020, 22, 470-483.	2.3	15
227	Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. <i>Nature Communications</i> , 2020, 11, 5376.	5.8	67
228	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 996.	1.3	14
229	Incremental prognostic value and underlying biological pathways of radiomics patterns in medulloblastoma. <i>EBioMedicine</i> , 2020, 61, 103093.	2.7	23
230	Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	24
231	Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa079.	0.4	5
232	Characterization of G-CSF receptor expression in medulloblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa062.	0.4	6
233	Super-sonic speed of DNA synthesis in medulloblastoma. <i>Nature Cancer</i> , 2020, 1, 758-760.	5.7	2
235	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	5.8	75
236	Wnt activation as a therapeutic strategy in medulloblastoma. <i>Nature Communications</i> , 2020, 11, 4323.	5.8	34
237	Ion Channels in Cancer: Orchestrators of Electrical Signaling and Cellular Crosstalk. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 103-133.	0.9	9
238	Neurotrophin Signaling in Medulloblastoma. <i>Cancers</i> , 2020, 12, 2542.	1.7	25
239	Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2020, 8, e1429.	0.6	3
240	Medulloblastoma epigenetics and the path to clinical innovation. <i>Journal of Neuro-Oncology</i> , 2020, 150, 35-46.	1.4	7
241	Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137. <i>Cell Death and Disease</i> , 2020, 11, 1029.	2.7	25

#	ARTICLE	IF	CITATIONS
242	Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1. <i>Cancer Management and Research</i> , 2020, Volume 12, 12473-12485.	0.9	5
243	Immunotherapy for Medulloblastoma: Current Perspectives. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 57-77.	2.7	33
244	Construction and Validation of a 13-Genes Signature for Prognosis Prediction in Medulloblastoma. <i>Frontiers in Genetics</i> , 2020, 11, 429.	1.1	6
245	A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1351-1362.	1.9	10
246	Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy. <i>Journal of Pathology</i> , 2020, 251, 249-261.	2.1	53
247	Current medulloblastoma subgroup specific clinical trials. <i>Translational Pediatrics</i> , 2020, 9, 157-162.	0.5	32
248	Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 70.	2.4	11
249	Epigenetics and survivorship in pediatric brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2020, 150, 77-83.	1.4	3
250	Embryonal Tumors of the Central Nervous System. <i>Surgical Pathology Clinics</i> , 2020, 13, 235-247.	0.7	12
251	Can gliomas provide insights into promoting synaptogenesis?. <i>Molecular Psychiatry</i> , 2020, 25, 1920-1925.	4.1	0
252	Pediatric Posterior Fossa Medulloblastoma: The Role of Diffusion Imaging in Identifying Molecular Groups. <i>Journal of Neuroimaging</i> , 2020, 30, 503-511.	1.0	9
253	Autophagy in cancers including brain tumors: role of MicroRNAs. <i>Cell Communication and Signaling</i> , 2020, 18, 88.	2.7	40
254	Identification of Core Genes and Pathways in Medulloblastoma by Integrated Bioinformatics Analysis. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 1702-1712.	1.1	6
255	Nuclear Receptor Binding Protein 2 Is Downregulated in Medulloblastoma, and Reduces Tumor Cell Survival upon Overexpression. <i>Cancers</i> , 2020, 12, 1483.	1.7	6
256	Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 30.	2.0	9
257	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. <i>Pharmacological Reviews</i> , 2020, 72, 668-691.	7.1	6
258	The Non-coding Side of Medulloblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 275.	1.8	9
259	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	3.9	45

#	ARTICLE	IF	CITATIONS
260	Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020, 148, 619-628.	1.4	8
261	A 21-Month-Old Boy with One-Month History of Vomiting. <i>Brain Pathology</i> , 2020, 30, 425-426.	2.1	0
262	Network Diffusion Promotes the Integrative Analysis of Multiple Omics. <i>Frontiers in Genetics</i> , 2020, 11, 106.	1.1	21
263	Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. <i>Journal of Neuro-Oncology</i> , 2020, 147, 531-545.	1.4	10
264	MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). <i>Brain Pathology</i> , 2020, 30, 732-745.	2.1	35
265	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
266	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. <i>Cancers</i> , 2020, 12, 643.	1.7	13
267	Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. <i>Cancers</i> , 2020, 12, 653.	1.7	8
268	CITK Loss Inhibits Growth of Group 3 and Group 4 Medulloblastoma Cells and Sensitizes Them to DNA-Damaging Agents. <i>Cancers</i> , 2020, 12, 542.	1.7	14
269	Prospects and challenges for use of CAR T cell therapies in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 503-516.	1.4	37
270	Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106028.	0.6	3
271	Integrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools. <i>Frontiers in Oncology</i> , 2020, 10, 1030.	1.3	134
272	Integrative Network Fusion: A Multi-Omics Approach in Molecular Profiling. <i>Frontiers in Oncology</i> , 2020, 10, 1065.	1.3	30
273	Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. <i>Nature Communications</i> , 2020, 11, 3406.	5.8	300
274	Medulloblastoma: an Old Diagnosis with New Promises. <i>Current Oncology Reports</i> , 2020, 22, 90.	1.8	13
275	YBX1 Indirectly Targets Heterochromatin-Repressed Inflammatory Response-Related Apoptosis Genes through Regulating CBX5 mRNA. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4453.	1.8	11
276	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	3.3	24
277	Engineered hydrogels for brain tumor culture and therapy. <i>Bio-Design and Manufacturing</i> , 2020, 3, 203-226.	3.9	24



#	ARTICLE	IF	CITATIONS
278	Pediatric medulloblastoma in the molecular era: what are the surgical implications?. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 235-243.	2.7	2
279	Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas. <i>Cell Cycle</i> , 2020, 19, 727-741.	1.3	5
280	HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 981-992.	1.1	21
281	Medulloblastoma: Molecular understanding, treatment evolution, and new developments. , 2020, 210, 107516.		37
282	Methylation-based algorithms for diagnosis: experience from neuro-oncology. <i>Journal of Pathology</i> , 2020, 250, 510-517.	2.1	25
283	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 437-447.	0.9	19
284	Preclinical Models of Craniospinal Irradiation for Medulloblastoma. <i>Cancers</i> , 2020, 12, 133.	1.7	4
285	Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 211-233.	2.7	42
286	An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling. <i>Cancer Research</i> , 2020, 80, 1524-1537.	0.4	10
287	The AHR pathway represses TGF $\beta$ 2-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. <i>Scientific Reports</i> , 2020, 10, 148.	1.6	22
288	Invited Review: DNA methylation-based classification of paediatric brain tumours. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 28-47.	1.8	33
289	Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup. <i>Scientific Reports</i> , 2020, 10, 6836.	1.6	10
290	Genomics Paves the Way for Better Infant Medulloblastoma Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2010-2013.	0.8	14
291	Neuro-oncology in adolescents and young adults—“an unmet need. <i>Neuro-Oncology</i> , 2020, 22, 752-753.	0.6	1
292	Pathology, diagnostics, and classification of medulloblastoma. <i>Brain Pathology</i> , 2020, 30, 664-678.	2.1	68
293	Mini-symposium in medulloblastoma genomics in the modern molecular era. <i>Brain Pathology</i> , 2020, 30, 661-663.	2.1	16
294	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	0.8	58
295	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <i>Nature Medicine</i> , 2020, 26, 720-731.	15.2	141

#	ARTICLE	IF	CITATIONS
296	In silico analysis of long non-coding RNAs in medulloblastoma and its subgroups. <i>Neurobiology of Disease</i> , 2020, 141, 104873.	2.1	18
297	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on Head Start-III: a multi-institutional, prospective clinical trial. <i>Neuro-Oncology</i> , 2020, 22, 1862-1872.	0.6	57
298	Medulloblastoma: A turning point from fundamental advances to improved survival and decreased sequelae. <i>Neurochirurgie</i> , 2021, 67, 3-5.	0.6	1
299	Abnormal spindle-like microcephaly-associated (ASPM) gene expression in posterior fossa brain tumors of childhood and adolescence. <i>Child's Nervous System</i> , 2021, 37, 137-145.	0.6	1
301	Medulloblastomas in adolescents and adults – Can the pediatric experience be extrapolated?. <i>Neurochirurgie</i> , 2021, 67, 76-82.	0.6	7
302	New research directions in medulloblastoma. <i>Neurochirurgie</i> , 2021, 67, 87-89.	0.6	3
303	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. <i>Oncogene</i> , 2021, 40, 396-407.	2.6	35
304	The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 236-250.	1.8	12
305	Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 488-504.	5.7	16
306	Clinically and biologically relevant subgroups of Wilms tumour defined by genomic and epigenomic analyses. <i>British Journal of Cancer</i> , 2021, 124, 437-446.	2.9	16
307	Downregulation of miR-326 and its host gene p27 <sup>Arrestin1</sup> induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	2.1	8
308	The 100 Most Influential Publications on Medulloblastoma: Areas of Past, Current, and Future Focus. <i>World Neurosurgery</i> , 2021, 146, 119-139.	0.7	10
309	GLI3 Is Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 129-136.	0.9	5
310	Deconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond. <i>Trends in Genetics</i> , 2021, 37, 235-250.	2.9	40
311	Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?. <i>Molecular Cancer Research</i> , 2021, 19, 375-387.	1.5	4
312	Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma. <i>Cancer Letters</i> , 2021, 499, 220-231.	3.2	22
313	Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier. <i>Neuro-Oncology</i> , 2021, 23, 732-742.	0.6	12
314	3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome. <i>Journal of Pathology</i> , 2021, 253, 326-338.	2.1	6

#	ARTICLE	IF	CITATIONS
315	An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma. <i>Neuro-Oncology</i> , 2021, 23, 586-598.	0.6	8
316	Computational Analysis of Phosphoproteomics Data in Multi-Omics Cancer Studies. <i>Proteomics</i> , 2021, 21, e1900312.	1.3	20
317	Long non-coding RNAs in brain tumors. <i>NAR Cancer</i> , 2021, 3, zcaa041.	1.6	12
318	A systematic view of pediatric medulloblastoma proteomics—current state of the field and future directions. <i>Child's Nervous System</i> , 2021, 37, 779-788.	0.6	1
319	Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age. <i>Cancer Research</i> , 2021, 81, 264-265.	0.4	0
320	A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma. <i>Cancers</i> , 2021, 13, 387.	1.7	11
321	Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab097.	0.4	5
322	Arginine Methylation in Brain Tumors: Tumor Biology and Therapeutic Strategies. <i>Cells</i> , 2021, 10, 124.	1.8	15
323	Differences in RNA and microRNA Expression Between PTCH1- and SUFU-mutated Medulloblastoma. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 335-347.	1.0	4
324	Pre- and Post-Treatment Imaging of Primary Central Nervous System Tumors in the Molecular and Genetic Era. <i>Korean Journal of Radiology</i> , 2021, 22, 1858-1874.	1.5	4
325	Heparan Sulfate in Normal and Cancer Stem Cells of the Brain. <i>Biology of Extracellular Matrix</i> , 2021, , 205-236.	0.3	0
326	DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. <i>Oncolmmunology</i> , 2021, 10, 1932365.	2.1	17
327	NK cells in brain tumors: From biology to treatment. , 2021, , 477-502.		1
328	Molecular Determinants of Medulloblastoma Metastasis and Leptomeningeal Dissemination. <i>Molecular Cancer Research</i> , 2021, 19, 743-752.	1.5	14
329	Neonatal and Perinatal Solid Tumors. , 2021, , 382-400.		0
330	Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas. <i>Neurochirurgie</i> , 2021, 67, 39-45.	0.6	6
331	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	0.6	7
332	Genomic and Transcriptomic Analyses Reveals ZNF124 as a Critical Regulator in Highly Aggressive Medulloblastomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 634056.	1.8	11

#	ARTICLE	IF	CITATIONS
333	Surgical management of posterior fossa medulloblastoma in children: The Lyon experience. <i>Neurochirurgie</i> , 2021, 67, 52-60.	0.6	5
334	Adolescent and young adult neuro-oncology: a comprehensive review. <i>Neuro-Oncology Practice</i> , 2021, 8, 236-246.	1.0	5
335	3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. <i>Scientific Reports</i> , 2021, 11, 4259.	1.6	20
336	In vitro Modeling of Embryonal Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640633.	1.8	3
337	Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 603686.	1.3	4
338	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	0.6	46
339	REST promotes ETS1-dependent vascular growth in medulloblastoma. <i>Molecular Oncology</i> , 2021, 15, 1486-1506.	2.1	9
340	Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. <i>Scientific Reports</i> , 2021, 11, 5374.	1.6	9
341	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. , 2021, 228, 107828.		7
342	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
343	Topoisomerase II $\beta$ immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group. <i>Brain Tumor Pathology</i> , 2021, 38, 109-121.	1.1	1
344	Multifaceted microglia "key players in primary brain tumour heterogeneity. <i>Nature Reviews Neurology</i> , 2021, 17, 243-259.	4.9	27
345	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	0.8	106
346	Novel Molecular Hallmarks of Group 3 Medulloblastoma by Single-Cell Transcriptomics. <i>Frontiers in Oncology</i> , 2021, 11, 622430.	1.3	4
347	Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo. <i>Cancers</i> , 2021, 13, 1220.	1.7	8
348	Medulloblastoma (cross)talk through extracellular vesicles. <i>Neuro-Oncology</i> , 2021, 23, 527-529.	0.6	1
349	CENPE Inhibition Leads to Mitotic Catastrophe and DNA Damage in Medulloblastoma Cells. <i>Cancers</i> , 2021, 13, 1028.	1.7	12
350	Statins repress hedgehog signaling in medulloblastoma with no bone toxicities. <i>Oncogene</i> , 2021, 40, 2258-2272.	2.6	10

#	ARTICLE	IF	CITATIONS
351	From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma. <i>FEBS Journal</i> , 2021, , .	2.2	6
352	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
353	Imaging of brain tumors in children: the basicsâ€”a narrative review. <i>Translational Pediatrics</i> , 2021, 10, 1138-1168.	0.5	5
354	Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles. <i>Science Advances</i> , 2021, 7, .	4.7	47
355	Esami citologici, istologici, immunoistochimici e genetici dei tumori del sistema nervoso centrale. <i>EMC - Neurologia</i> , 2021, 21, 1-21.	0.0	0
356	Ten-eleven translocation protein 1 modulates medulloblastoma progression. <i>Genome Biology</i> , 2021, 22, 125.	3.8	3
357	Semaphorin Regulation by the Chromatin Remodeler CHD7: An Emerging Genetic Interaction Shaping Neural Cells and Neural Crest in Development and Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 638674.	1.8	5
358	In Vivo and Ex Vivo Pediatric Brain Tumor Models: An Overview. <i>Frontiers in Oncology</i> , 2021, 11, 620831.	1.3	15
359	Circular RNA profiling distinguishes medulloblastoma groups and shows aberrant RMST overexpression in WNT medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 141, 975-978.	3.9	12
360	BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion, and Expression of PRC2 Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3913.	1.8	0
361	Epigenomics and immunotherapeutic advances in pediatric brain tumors. <i>Npj Precision Oncology</i> , 2021, 5, 34.	2.3	9
362	Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. <i>Cell Reports</i> , 2021, 35, 109013.	2.9	18
363	New Approaches in Targeted Therapy for Medulloblastoma in Children. <i>Anticancer Research</i> , 2021, 41, 1715-1726.	0.5	15
364	Infantile Brain Tumors: A Review of Literature and Future Perspectives. <i>Diagnostics</i> , 2021, 11, 670.	1.3	4
365	MEVITEMâ€”a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. <i>Neuro-Oncology</i> , 2021, 23, 1949-1960.	0.6	20
366	ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. <i>Cancers</i> , 2021, 13, 1989.	1.7	26
367	Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. <i>Nature Communications</i> , 2021, 12, 2148.	5.8	20
369	Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 367-384.	4.0	12

#	ARTICLE	IF	CITATIONS
370	Recurrent Wnt medulloblastoma treated with marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue: a dual case report and review of the literature. <i>Child's Nervous System</i> , 2021, , 1.	0.6	1
372	CLEP: a hybrid data- and knowledge-driven framework for generating patient representations. <i>Bioinformatics</i> , 2021, 37, 3311-3318.	1.8	6
373	Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth. <i>Communications Biology</i> , 2021, 4, 552.	2.0	5
374	Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways. <i>Human Molecular Genetics</i> , 2021, 30, 1721-1733.	1.4	8
375	The mammalian Hedgehog pathway is modulated by ANP32 proteins. <i>Biochemical and Biophysical Research Communications</i> , 2021, 553, 78-84.	1.0	6
376	Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile. <i>Communications Biology</i> , 2021, 4, 616.	2.0	13
377	Gene expression signatures predict response to therapy with growth hormone. <i>Pharmacogenomics Journal</i> , 2021, 21, 594-607.	0.9	2
379	Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. <i>Genome Medicine</i> , 2021, 13, 103.	3.6	10
380	Navigating the DNA methylation landscape of cancer. <i>Trends in Genetics</i> , 2021, 37, 1012-1027.	2.9	308
381	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
382	Multi-omics analysis of intertumoral heterogeneity within medulloblastoma uncharted-pathway subtypes. <i>Brain Tumor Pathology</i> , 2021, 38, 234-242.	1.1	4
383	Stem-Like Cell Populations, p53-Pathway Activation and Mechanisms of Recurrence in Sonic Hedgehog Medulloblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 13-17.	1.8	5
384	Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, 273-286.	0.6	52
385	Dissecting adult SHH-activated medulloblastoma—molecularly defined tumor subsets reveal new prognostic biomarkers. <i>Neuro-Oncology</i> , 2021, 23, 1425-1426.	0.6	0
386	Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models. <i>Cancer Science</i> , 2021, 112, 2948-2957.	1.7	4
387	Sterol regulation of developmental and oncogenic Hedgehog signaling. <i>Biochemical Pharmacology</i> , 2022, 196, 114647.	2.0	11
388	Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 674596.	1.3	7
389	Classifying Medulloblastoma Subgroups Based on Small, Clinically Achievable Gene Sets. <i>Frontiers in Oncology</i> , 2021, 11, 637482.	1.3	6

#	ARTICLE	IF	CITATIONS
390	Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. <i>Frontiers in Oncology</i> , 2021, 11, 694320.	1.3	11
391	Immune cell landscape and immunotherapy of medulloblastoma. <i>Pediatric Investigation</i> , 2021, 5, 299-309.	0.6	9
392	Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination. <i>Cell Reports</i> , 2021, 35, 109302.	2.9	19
393	Overview and recent advances in the targeting of medulloblastoma cancer stem cells. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 957-974.	1.1	5
395	Notch1 switches progenitor competence in inducing medulloblastoma. <i>Science Advances</i> , 2021, 7, .	4.7	6
396	Exploring the role and clinical implications of proteasome inhibition in medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29168.	0.8	1
397	Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. <i>Acta Neuropathologica</i> , 2021, 142, 537-564.	3.9	21
398	Updates on the 2016 World Health Organization Classification of Pediatric Tumors of the Central Nervous System - a systematic review. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 282-288.	0.2	7
399	Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes. <i>Molecules and Cells</i> , 2021, 44, 433-443.	1.0	57
400	Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
401	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, 153-165.	0.6	28
402	SOX9 Defines Distinct Populations of Cells in SHH Medulloblastoma but Is Not Required for Math1-Driven Tumor Formation. <i>Molecular Cancer Research</i> , 2021, 19, 1831-1839.	1.5	5
403	The multifaceted NF- $\kappa$ B: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 6161-6200.	2.4	10
404	Single-cell spatial transcriptomic analysis reveals common and divergent features of developing postnatal granule cerebellar cells and medulloblastoma. <i>BMC Biology</i> , 2021, 19, 135.	1.7	20
405	Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma. <i>Cancers</i> , 2021, 13, 3853.	1.7	4
406	Understanding the global impact of primary brain tumors: The untapped potential of population-based cancer registries. <i>Neuro-Oncology</i> , 2021, 23, 1625-1626.	0.6	0
407	MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma. <i>Human Molecular Genetics</i> , 2021, 30, 2416-2428.	1.4	11
408	Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets. <i>Oncogene</i> , 2021, 40, 5213-5223.	2.6	1

#	ARTICLE	IF	CITATIONS
409	Magnetic resonance radiomics features and prognosticators in different molecular subtypes of pediatric Medulloblastoma. PLoS ONE, 2021, 16, e0255500.	1.1	16
410	Pediatric Neuro-Oncology. Neurologic Clinics, 2021, 39, 829-845.	0.8	12
411	Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Current Problems in Cancer, 2021, 45, 100777.	1.0	17
413	Calcium Signalling in Medulloblastoma: An In Silico Analysis of the Expression of Calcium Regulating Genes in Patient Samples. Genes, 2021, 12, 1329.	1.0	4
414	MethylSPWNet and MethylCapsNet: Biologically Motivated Organization of DNAm Neural Networks, Inspired by Capsule Networks. Npj Systems Biology and Applications, 2021, 7, 33.	1.4	12
415	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
416	CREB signaling activity correlates with differentiation and survival in medulloblastoma. Scientific Reports, 2021, 11, 16077.	1.6	2
417	Decoding the Roles of Astrocytes and Hedgehog Signaling in Medulloblastoma. Current Oncology, 2021, 28, 3058-3070.	0.9	2
418	Disruption of rack1 suppresses SHH-type medulloblastoma formation in mice. CNS Neuroscience and Therapeutics, 2021, 27, 1518-1530.	1.9	3
419	Role of mammalian long non-coding RNAs in normal and neuro oncological disorders. Genomics, 2021, 113, 3250-3273.	1.3	5
420	DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker. Clinical Epigenetics, 2021, 13, 176.	1.8	9
421	High expression of Toll-like receptor 7 is a survival factor in pediatric medulloblastoma. Child's Nervous System, 2021, 37, 3743-3752.	0.6	3
422	A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-Oncology, 2022, 24, 414-426.	0.6	15
424	Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma. Child's Nervous System, 2021, 37, 3733-3742.	0.6	2
425	Extracellular Matrix Proteome Remodeling in Human Glioblastoma and Medulloblastoma. Journal of Proteome Research, 2021, 20, 4693-4707.	1.8	12
426	Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation. Cancer Letters, 2021, 520, 201-212.	3.2	12
427	Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications. Molecular Therapy - Nucleic Acids, 2021, 26, 417-431.	2.3	6
429	Medulloblastoma in adults – reviewing the literature from a surgeon's point of view. Aging, 2021, 13, 3146-3160.	1.4	0



#	ARTICLE	IF	CITATIONS
430	Assessment of Cannabidiol and $\delta^9$ -Tetrahydrocannabinol in Mouse Models of Medulloblastoma and Ependymoma. <i>Cancers</i> , 2021, 13, 330.	1.7	21
431	Pathology and Molecular Biology of Medulloblastoma. , 2021, , 79-88.		0
432	Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab079.	0.4	6
433	Targeting MYCN in Molecularly Defined Malignant Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 626751.	1.3	18
434	Involvement of Heparan Sulfate and Heparanase in Neural Development and Pathogenesis of Brain Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1221, 365-403.	0.8	9
435	FHOD3 promotes carcinogenesis by regulating RhoA/ROCK1/LIMK1 signaling pathway in medulloblastoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 2312-2323.	1.2	4
436	Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 957-966.	1.2	11
437	The long noncoding RNA <i>lnc-HLX-2-7</i> is oncogenic in Group 3 medulloblastomas. <i>Neuro-Oncology</i> , 2021, 23, 572-585.	0.6	23
438	Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5. <i>Neuro-Oncology</i> , 2021, 23, 1163-1172.	0.6	23
445	The Eya1 Phosphatase Mediates Shh-Driven Symmetric Cell Division of Cerebellar Granule Cell Precursors. <i>Developmental Neuroscience</i> , 2020, 42, 170-186.	1.0	10
446	Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. <i>JCI Insight</i> , 2019, 4, .	2.3	20
447	Misactivation of Hedgehog signaling causes inherited and sporadic cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 465-475.	3.9	72
448	Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment. <i>F1000Research</i> , 2019, 8, 1823.	0.8	13
449	MAP4K4 controlled integrin $\beta$ 21 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. <i>Oncotarget</i> , 2018, 9, 23220-23236.	0.8	32
450	MRI-based prediction of molecular subgrouping in medulloblastoma: images speak louder than words. <i>Oncotarget</i> , 2019, 10, 4805-4807.	0.8	2
451	Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. <i>Current Cancer Drug Targets</i> , 2019, 19, 571-582.	0.8	10
452	Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. <i>Current Neuropharmacology</i> , 2018, 16, 1045-1058.	1.4	39
453	Medulloblastoma in the Molecular Era. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 292-301.	0.5	22

#	ARTICLE	IF	CITATIONS
454	Immune cell infiltration and cytokine secretion analysis reveal a non-inflammatory microenvironment of medulloblastoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	19
455	Brain tumors: Cancer stem-like cells interact with tumor microenvironment. <i>World Journal of Stem Cells</i> , 2020, 12, 1439-1454.	1.3	3
456	Medulloblastoma: novel insights into emerging therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 615-619.	1.5	2
458	Functional Genomics of PRUNE1 in Neurodevelopmental Disorders (NDDs) Tied to Medulloblastoma (MB) and Other Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 758146.	1.3	7
459	Integrated computational analyses reveal novel insights into the stromal microenvironment of SHH-subtype medulloblastoma. <i>Scientific Reports</i> , 2021, 11, 20694.	1.6	2
460	mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma. <i>JCI Insight</i> , 2021, 6, .	2.3	3
461	EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11292.	1.8	8
462	Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future. <i>Molecular Biology Reports</i> , 2021, 48, 7537-7544.	1.0	0
463	Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. <i>Molecular Cancer Research</i> , 2022, 20, 114-126.	1.5	11
465	Pediatric Chemotherapy. , 2018, , 1-15.		0
470	Genomic Applications in Brain Tumors. , 2019, , 289-308.		0
474	Treatment of children with medulloblastoma without metastatic involvement in the age group older than 3 years: international experience and results of intercenter trial. <i>Journal of Modern Oncology</i> , 2020, 22, 66-76.	0.1	0
485	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128.	3.2	8
486	Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. <i>Cancers</i> , 2021, 13, 5387.	1.7	11
487	Is adult medulloblastoma merely the counterpart of pediatric medulloblastoma?. <i>Glioma (Mumbai)</i> , Tj ETQqO 0 0 rgBT/Overlock 10 Tf 50	0.0	0
488	Clinical Aggressiveness of <i>TP53</i> -Wild Type Sonic Hedgehog Medulloblastoma With <i>MYCN</i> Amplification, Chromosome 17p Loss, and Chromothripsis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 205-207.	0.9	1
490	Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation Analysis. <i>American Journal of Surgical Pathology</i> , 2021, 45, 558-566.	2.1	7
491	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. <i>PLoS ONE</i> , 2020, 15, e0243272.	1.1	2

#	ARTICLE	IF	CITATIONS
492	Expression and clinical importance of a newly discovered alternative splice variant of the gene for acrosin binding protein found in human brain tumors. <i>Asian Biomedicine</i> , 2020, 14, 243-252.	0.2	2
493	Mechanisms of telomere maintenance in pediatric brain tumors: Promising targets for therapy – A narrative review. <i>Glioma (Mumbai, India)</i> , 2020, 3, 105.	0.0	1
494	Pediatric cerebellar tumors: transcriptionally distinct but developmentally heterogeneous. <i>Translational Cancer Research</i> , 2020, 9, 1322-1325.	0.4	0
496	Central Nervous System Tumor Classification. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 1-21.	0.9	1
497	In Vivo Medulloblastoma Modeling. <i>Neuromethods</i> , 2021, , 39-58.	0.2	0
499	A transcriptome-based classifier to determine molecular subtypes in medulloblastoma. <i>PLoS Computational Biology</i> , 2020, 16, e1008263.	1.5	6
500	Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients. <i>Aging</i> , 2020, 12, 21481-21503.	1.4	3
501	Ubiquitin ligases and medulloblastoma: genetic markers of the four consensus subgroups identified through transcriptome datasets. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165839.	1.8	7
502	Embryonal Tumors of the Central Nervous System: The WHO 2016 Classification and New Insights. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 79-89.	0.3	2
503	Genomics of adult and pediatric solid tumors. <i>American Journal of Cancer Research</i> , 2018, 8, 1356-1386.	1.4	14
504	Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2018, 9, 43-54.	0.4	2
505	Interactions between antibiotics and heavy metals determine their combined toxicity to <i>Synechocystis</i> sp.. <i>Journal of Hazardous Materials</i> , 2022, 424, 127707.	6.5	25
506	ONC201/TIC10 Is Empowered by 2-Deoxyglucose and Causes Metabolic Reprogramming in Medulloblastoma Cells in Vitro Independent of C-Myc Expression. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 734699.	1.8	2
507	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021, 7, eabg9551.	4.7	49
508	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 756025.	1.3	3
509	Identification of TPST1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 633-641.	1.1	6
510	Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis. <i>Scientific Reports</i> , 2021, 11, 23282.	1.6	7
512	Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies. <i>Methods in Molecular Biology</i> , 2022, 2423, 215-235.	0.4	3

#	ARTICLE	IF	CITATIONS
513	Predicting Kinase-Substrate Interactions in Medulloblastoma Subtypes. , 2020, , .		0
514	Molecular and clinical correlates of medulloblastoma subgroups: A narrative review. Glioma (Mumbai, India), 2021, 4, 92.	0.0	2
515	CAR-T cells for pediatric brain tumors: Present and future. Bulletin Du Cancer, 2021, 108, S109-S116.	0.6	1
516	Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape. Cancers, 2021, 13, 6251.	1.7	12
517	Role of Precision Medicine in Pediatric Oncology. Pediatric Annals, 2022, 51, e8-e14.	0.3	3
519	Applications of noncoding RNAs in brain cancer patients. , 2022, , 17-64.		0
520	Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy. Methods in Molecular Biology, 2022, 2423, 123-140.	0.4	1
521	Identification of a glioma functional network from gene fitness data using machine learning. Journal of Cellular and Molecular Medicine, 2022, 26, 1253-1263.	1.6	3
522	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. Cancers, 2022, 14, 471.	1.7	9
523	Primary leptomeningeal medulloblastoma: a case-based review. Child's Nervous System, 2022, 38, 527-536.	0.6	0
524	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	1.7	16
525	Progress and possibilities for patient-derived iPSCs and genetically engineered stem cells in cancer modeling and targeted therapies. , 2022, , 247-288.		1
526	Central Nervous System Tumors in Children. Pediatrics in Review, 2022, 43, 3-15.	0.2	1
527	Treatment of medulloblastoma in pediatric patients over 3 years old: modern approaches with respect to molecular and biologic tumor features. Medical Alphabet, 2022, , 26-31.	0.0	0
528	Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination. Current Protocols, 2022, 2, e357.	1.3	9
529	Childhood Medulloblastoma: An Overview. Methods in Molecular Biology, 2022, 2423, 1-12.	0.4	5
530	The Molecular Landscape of Medulloblastoma in Teenagers and Young Adults. Cancers, 2022, 14, 251.	1.7	1
531	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	1.7	4

#	ARTICLE	IF	CITATIONS
532	Integration of immunohistochemistry, RNA sequencing, and multiplex ligation-dependent probe amplification for molecular classification of pediatric medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29569.	0.8	1
533	Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification. <i>Journal of Korean Medical Science</i> , 2022, 37, e59.	1.1	1
534	Discovery of HDAC6-Selective Inhibitor NN-390 with <i>in Vitro</i> Efficacy in Group 3 Medulloblastoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3193-3217.	2.9	16
535	C9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 392-398.	1.8	4
536	MiR-212-3p functions as a tumor suppressor gene in group 3 medulloblastoma via targeting nuclear factor I/B (NFIB). <i>Acta Neuropathologica Communications</i> , 2021, 9, 195.	2.4	9
537	Role of MicroRNAs in the Development and Progression of the Four Medulloblastoma Subgroups. <i>Cancers</i> , 2021, 13, 6323.	1.7	4
538	The Architecture of a Precision Oncology Platform. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 1-22.	0.8	1
539	Network Approaches for Precision Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 199-213.	0.8	1
540	Medulloblastoma: WHO 2021 and Beyond. <i>Pediatric and Developmental Pathology</i> , 2022, 25, 23-33.	0.5	18
541	OUP accepted manuscript. <i>Neuro-Oncology</i> , 2022, , .	0.6	0
542	Artificial Intelligence for Precision Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 249-268.	0.8	10
543	Epigenetic mechanisms in paediatric brain tumours: regulators lose control. <i>Biochemical Society Transactions</i> , 2022, 50, 167-185.	1.6	3
544	Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs. <i>Acta Neuropathologica Communications</i> , 2022, 10, 25.	2.4	21
546	Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1273-1285.	0.6	8
547	Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study. <i>Journal of Neuro-Oncology</i> , 2022, 157, 27-35.	1.4	2
548	Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 49.	7.1	11
549	Predictive modeling of resistance to SMO-inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vda026.	0.4	1
550	Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. <i>Neuro-Oncology</i> , 2022, 24, 1509-1523.	0.6	12

#	ARTICLE	IF	CITATIONS
551	Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac031.	0.4	1
552	Spatial proteomics finds CD155 and Endophilin-A1 as mediators of growth and invasion in medulloblastoma. <i>Life Science Alliance</i> , 2022, 5, e202201380.	1.3	5
553	Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 72.	7.1	4
554	Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3815.	1.8	1
555	Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets. <i>Frontiers in Immunology</i> , 2022, 13, 837013.	2.2	1
556	Pediatric brain tumors: a bibliometric analysis. <i>Child's Nervous System</i> , 2022, , 1.	0.6	5
557	Medulloblastoma: Immune microenvironment and targeted nano-therapy. <i>OpenNano</i> , 2022, 6, 100035.	1.8	0
558	Clinical Prognostic Implications of Wnt Hub Genes Expression in Medulloblastoma. <i>Cellular and Molecular Neurobiology</i> , 2022, , 1.	1.7	2
560	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. <i>Cancers</i> , 2022, 14, 126.	1.7	12
561	Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. <i>Cancers</i> , 2022, 14, 70.	1.7	7
562	Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma. <i>Cancers</i> , 2022, 14, 139.	1.7	3
563	Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age. <i>Cancers</i> , 2021, 13, 6313.	1.7	4
564	Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 464.	1.8	6
565	Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. <i>Science Advances</i> , 2021, 7, eabi5568.	4.7	8
566	Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. <i>Diagnostics</i> , 2022, 12, 61.	1.3	10
567	YAP1 Is a Potential Predictive Molecular Biomarker for Response to SMO Inhibitor in Medulloblastoma Cells. <i>Cancers</i> , 2021, 13, 6249.	1.7	1
568	Childhood Malignant Brain Tumors: Balancing the Bench and Bedside. <i>Cancers</i> , 2021, 13, 6099.	1.7	15
570	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70

#	ARTICLE	IF	CITATIONS
571	The RNA-Binding Protein Musashi1 Regulates a Network of Cell Cycle Genes in Group 4 Medulloblastoma. <i>Cells</i> , 2022, 11, 56.	1.8	3
572	MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. <i>Radiology</i> , 2022, 304, 406-416.	3.6	27
573	Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activationâ€driven medulloblastoma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1033-1044.	1.9	2
583	Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies. <i>Methods in Molecular Biology</i> , 2022, 2475, 1-23.	0.4	2
584	Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions. <i>Anticancer Research</i> , 2022, 42, 2225-2239.	0.5	11
585	Rare CNS tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas and intracranial germ cell tumors. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	0
586	Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma. <i>Cancers</i> , 2022, 14, 2095.	1.7	2
587	Enrichment of Tumor-Infiltrating B Cells in Group 4 Medulloblastoma in Children. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5287.	1.8	4
588	Pediatric Pan-Central Nervous System Tumor Methylome Analyses Reveal Immune-Related LncRNAs. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
589	Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 402-416.	0.7	2
590	Cross-Talk Between Histone Methyltransferases and Demethylases Regulate REST Transcription During Neurogenesis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
591	High-throughput single-Ñell sequencing in cancer research. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 145.	7.1	39
592	The developmental stage of the medulloblastoma cell-of-origin restricts Sonic hedgehog pathway usage and drug sensitivity. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	2
593	An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 2760-2767.	2.0	9
594	Identification of PBK as a hub gene and potential therapeutic target for medulloblastoma. <i>Oncology Reports</i> , 2022, 48, .	1.2	2
595	Paediatric brain tumours in Singapore: A 15-year epidemiological and outcome study. <i>Journal of Clinical Neuroscience</i> , 2022, 101, 154-161.	0.8	1
596	Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. <i>Pharmaceuticals</i> , 2022, 15, 665.	1.7	5
597	How do we approach the management of medulloblastoma in young children?. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
598	Medulloblastoma and the DNA Damage Response. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
599	Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis. <i>Laryngoscope Investigative Otolaryngology</i> , 2022, 7, 1224-1234.	0.6	4
600	OLIG2 Is a Determinant for the Relapse of <i>MYC</i> -Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 4278-4291.	3.2	3
601	Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. <i>Nature Reviews Cancer</i> , 2022, 22, 497-514.	12.8	40
602	ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma. <i>NeuroMolecular Medicine</i> , 0, , .	1.8	1
604	Circular and Fusion RNAs in Medulloblastoma Development. <i>Cancers</i> , 2022, 14, 3134.	1.7	7
605	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. <i>Acta Neuropathologica</i> , 2022, 144, 339-352.	3.9	5
606	Cancer risk and tumour spectrum in 172 patients with a germline <i>SUFU</i> pathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. <i>Journal of Medical Genetics</i> , 2022, 59, 1123-1132.	1.5	4
607	A gene dosage-dependent effect unveils NBS1 as both a haploinsufficient tumour suppressor and an essential gene for <i>SHH</i> medulloblastoma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	3
608	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases <i>SHH</i> medulloblastoma tumor progression. <i>Communications Biology</i> , 2022, 5, .	2.0	8
609	The <i>HHIP-AS1</i> lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human <i>SHH</i> -driven tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	16
610	Advanced Neuroimaging Approaches to Pediatric Brain Tumors. <i>Cancers</i> , 2022, 14, 3401.	1.7	8
611	Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development. <i>Acta Neuropathologica</i> , 2022, 144, 565-578.	3.9	4
612	DNA methylation alterations across time and space in paediatric brain tumours. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	6
613	<i>TOP2A</i> correlates with poor prognosis and affects radioresistance of medulloblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
614	Noncanonical activation of <i>GLI</i> signaling in <i>SOX2</i> cells drives medulloblastoma relapse. <i>Science Advances</i> , 2022, 8, .	4.7	8
615	Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1306-1317.	1.9	1
616	Adult Medulloblastoma: Updates on Current Management and Future Perspectives. <i>Cancers</i> , 2022, 14, 3708.	1.7	7



#	ARTICLE	IF	CITATIONS
617	Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management. <i>Neurotherapeutics</i> , 2022, 19, 1733-1751.	2.1	13
618	The long non-coding RNA <i>SPRIGTLY</i> and its binding partner PTBP1 regulate exon 5 skipping of <i>SMYD3</i> transcripts in group 4 medulloblastomas. <i>Neuro-Oncology Advances</i> , 0, .	0.4	1
619	A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth. <i>Molecular Cancer Research</i> , 2022, 20, 1598-1610.	1.5	4
620	The role of methylation profiling in histologically diagnosed neurocytoma: a case series. <i>Journal of Neuro-Oncology</i> , 2022, 159, 725-733.	1.4	6
621	Heterozygous <i>BRCA1</i> and <i>BRCA2</i> and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1523-1532.	3.0	21
623	Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. <i>Cell Reports</i> , 2022, 40, 111162.	2.9	21
624	Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
625	Recent Advances of Utilizing Artificial Intelligence in Lab on a Chip for Diagnosis and Treatment. <i>Small</i> , 2022, 18, .	5.2	21
626	Cooperation of Striatin 3 and MAP4K4 promotes growth and tissue invasion. <i>Communications Biology</i> , 2022, 5, .	2.0	9
628	Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
629	Chromosomal Instability Characterizes Pediatric Medulloblastoma but Is Not Tolerated in the Developing Cerebellum. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9852.	1.8	1
630	Failure of human rhombic lip differentiation underlies medulloblastoma formation. <i>Nature</i> , 2022, 609, 1021-1028.	13.7	52
631	Miat and interacting protein Metadherin maintain a stem-like niche to promote medulloblastoma tumorigenesis and treatment resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
632	Imaging Embryonal Tumors of the Central Nervous System. <i>Advances in Clinical Radiology</i> , 2022, 4, 215-229.	0.1	0
633	Unified rhombic lip origins of group 3 and group 4 medulloblastoma. <i>Nature</i> , 2022, 609, 1012-1020.	13.7	44
635	Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
636	Advances on Epigenetic Drugs for Pediatric Brain Tumors. <i>Current Neuropharmacology</i> , 2023, 21, 1519-1535.	1.4	1
637	Updated classification of tumors of the central nervous system as the basis for individual patient therapy. , 2022, 2, 6-13.		1

#	ARTICLE	IF	CITATIONS
638	Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas. <i>Acta Neuropathologica</i> , 2022, 144, 1143-1156.	3.9	10
639	Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	5
640	Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach. <i>Cancers</i> , 2022, 14, 5128.	1.7	19
641	Epigenetic upregulation of Schlafen11 renders &#x201c;WNT- and SHH-activated medulloblastomas sensitive to cisplatin. <i>Neuro-Oncology</i> , 2023, 25, 899-912.	0.6	5
642	Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. <i>Neuro-Oncology</i> , 2023, 25, 520-530.	0.6	18
643	The Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential. <i>Cancers</i> , 2022, 14, 5009.	1.7	6
644	Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
645	Overview of molecular subtype of medulloblastoma and role of MRI in their identification. <i>International Journal of Radiology and Radiation Oncology</i> , 2022, 8, 005-010.	0.1	0
646	Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy. <i>Cancers</i> , 2022, 14, 4970.	1.7	5
647	Environmental Risk Factors for Childhood Central Nervous System Tumors: an Umbrella Review. <i>Current Epidemiology Reports</i> , 2022, 9, 338-360.	1.1	1
648	Molecular genetics of paediatric brain tumours and opportunities for precision medicine " a focus on infant tumours. <i>Current Opinion in Neurology</i> , 2022, 35, 772-778.	1.8	1
649	Cellular immunotherapy for medulloblastoma. <i>Neuro-Oncology</i> , 2023, 25, 617-627.	0.6	7
650	CD155 is a putative therapeutic target in medulloblastoma. <i>Clinical and Translational Oncology</i> , 2023, 25, 696-705.	1.2	3
651	METTL3 regulates m6A methylation of PTCH1 and GLI2 in Sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma. <i>Cell Reports</i> , 2022, 41, 111530.	2.9	22
652	Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma. <i>Cancer Research</i> , 2022, 82, 4586-4603.	0.4	8
653	Delta-catenin attenuates medulloblastoma cell invasion by targeting EMT pathway. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
655	Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity. <i>Neuron</i> , 2023, 111, 30-48.e14.	3.8	11
656	Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. <i>Cancer Cell</i> , 2022, 40, 1488-1502.e7.	7.7	24

#	ARTICLE	IF	CITATIONS
657	Whole-genome sequencing of extrachromosomal circular DNA of cerebrospinal fluid of medulloblastoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
658	Pediatric Brain Tumors in the Molecular Era: Updates for the Radiologist. <i>Seminars in Roentgenology</i> , 2023, 58, 47-66.	0.2	3
659	Immunohistochemical assessment and clinical, histopathologic, and molecular correlates of membranous somatostatin type-2A receptor expression in high-risk pediatric central nervous system tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
660	Sonic hedgehog signaling: Alternative splicing and pathogenic role in medulloblastoma. <i>Genes and Diseases</i> , 2023, 10, 2013-2028.	1.5	1
661	A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	4
662	Nanomedicine approaches for medulloblastoma therapy. <i>Journal of Pharmaceutical Investigation</i> , 2023, 53, 213-233.	2.7	6
663	Clinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan. <i>Cancers</i> , 2022, 14, 5419.	1.7	0
664	Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNO) disease working group. <i>Neoplasia</i> , 2023, 35, 100861.	2.3	4
665	Pediatric CNS Cancer Metastasis and the Immune System: A Dynamic Interplay. , 2022, , 1-11.		0
666	<sc>MRI</sc> Radiomics Signature of Pediatric Medulloblastoma Improves Risk Stratification Beyond Clinical and Conventional <sc>MR</sc> Imaging Features. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	2
667	Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
668	Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. <i>Nature</i> , 2022, 612, 787-794.	13.7	17
669	Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. <i>Acta Neuropathologica</i> , 2023, 145, 97-112.	3.9	7
671	Novel MRI deformation-heterogeneity radiomic features are associated with molecular subgroups and overall survival in pediatric medulloblastoma: Preliminary findings from a multi-institutional study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
672	Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. <i>Nature Communications</i> , 2022, 13, .	5.8	5
673	GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype. <i>Cancers</i> , 2022, 14, 6051.	1.7	2
674	Recent advances in the molecular understanding of medulloblastoma. <i>Cancer Science</i> , 2023, 114, 741-749.	1.7	8
675	Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas. <i>Cells</i> , 2022, 11, 3933.	1.8	0

#	ARTICLE	IF	CITATIONS
676	Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	4
677	Cell of Origin of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 85-101.	0.8	0
679	Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. , 2023, 11, e005871.		7
680	Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	7
681	Limitations of radiosensitization by direct telomerase inhibition to treat high-risk medulloblastoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
682	Case report: Somatic mutations in microtubule dynamics-associated genes in patients with WNT-medulloblastoma tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
683	LIN28 expression and function in medulloblastoma. <i>Journal of Cellular Physiology</i> , 2023, 238, 533-548.	2.0	3
684	Expression pattern of MRPS18 family genes in medulloblastoma: a case report. <i>Ukrainian Neurosurgical Journal</i> , 2022, 28, 35-40.	0.1	0
685	Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
686	Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	6
687	Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups. <i>Neuro-Oncology</i> , 0, , .	0.6	1
688	Medulloblastoma: Current Perspectives and Recent Advances. <i>Brain Tumor Research and Treatment</i> , 2023, 11, 28.	0.4	2
689	Epigenetics and immune cells in medulloblastoma. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
691	Timing is everything: A connection between medulloblastoma prognosis and fetal cerebellar development. <i>Neuropathology and Applied Neurobiology</i> , 0, , .	1.8	1
692	WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?. <i>Oncotarget</i> , 2023, 14, 105-110.	0.8	4
693	Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
694	Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. <i>Cancers</i> , 2023, 15, 1086.	1.7	4
695	Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	10

#	ARTICLE	IF	CITATIONS
696	The phosphorylation of PHF5A by TrkA-ERK1/2-ABL1 cascade regulates centrosome separation. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	0
697	Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. <i>Nature Communications</i> , 2023, 14, .	5.8	6
698	The pan-cancer landscape of abnormal DNA methylation and intratumor microorganisms. <i>Neoplasia</i> , 2023, 37, 100882.	2.3	0
699	A Simple, Test-Based Method to Control the Overestimation Bias in the Analysis of Potential Prognostic Tumour Markers. <i>Cancers</i> , 2023, 15, 1188.	1.7	0
700	Advances in NK cell therapy for brain tumors. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	8
702	Unusual manifestation of cerebellopontine angle medulloblastoma with tinnitus and sensorineural hearing loss. <i>Romanian Journal of Rhinology</i> , 2023, 13, 22-31.	0.1	0
704	PDLIM3 supports hedgehog signaling in medulloblastoma by facilitating cilia formation. <i>Cell Death and Differentiation</i> , 0, , .	5.0	1
705	Epigenetic Control and Cerebellar Neurodevelopmental Disorders. <i>Contemporary Clinical Neuroscience</i> , 2023, , 273-295.	0.3	0
706	Primary Pediatric Brain Tumors of the Posterior Fossa: Part II A Comprehensive Overview of Medulloblastoma. <i>Contemporary Clinical Neuroscience</i> , 2023, , 421-455.	0.3	0
707	A neurodevelopmental epigenetic programme mediated by SMARCD3â€“DAB1â€“Reelin signalling is hijacked to promote medulloblastoma metastasis. <i>Nature Cell Biology</i> , 2023, 25, 493-507.	4.6	10
708	Research progress in molecular pathology markers in medulloblastoma. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2023, 4, 139-156.	0.5	1
710	ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. <i>Nature Communications</i> , 2023, 14, .	5.8	4
712	A narrative review of what the neuropathologist needs to tell the clinician in neuro-oncology practice concerning WHO CNS5. <i>Glioma (Mumbai, India)</i> , 2022, 5, 120.	0.0	0
714	Identification of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5331.	1.8	2
715	Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol. <i>Journal of Neuro-Oncology</i> , 2023, 162, 225-235.	1.4	2
716	Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. <i>Nature Medicine</i> , 2023, 29, 917-926.	15.2	27
717	Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. <i>World Journal of Clinical Oncology</i> , 0, 14, 117-130.	0.9	1
718	Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
720	Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. <i>Cancer Cell</i> , 2023, 41, 660-677.e7.	7.7	7
721	Leptomeningeal dissemination in pediatric brain tumors. <i>Neoplasia</i> , 2023, 39, 100898.	2.3	3
722	Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. <i>Acta Neuropathologica</i> , 2023, 145, 651-666.	3.9	1
723	IGFBP2 promotes proliferation and cell migration through STAT3 signaling in Sonic hedgehog medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	0
724	STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo. <i>Cancers</i> , 2023, 15, 2239.	1.7	1
727	Pediatric Brain and Brainstem Tumors. , 2023, , 125-140.		0
741	Staging for Childhood Cancer Management. , 2023, , 1-41.		0
750	Neuroimaging of Brain Tumors in the Era of Radiogenomics. , 2023, , 1275-1311.		0
757	The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target. <i>Oncogene</i> , 2023, 42, 2363-2373.	2.6	6
773	Tumorsphere Formation Assay: A Cancer Stem-Like Cell Characterization in Pediatric Brain Cancer Medulloblastoma. <i>Methods in Molecular Biology</i> , 2023, , 253-259.	0.4	0
781	Posterior fossa tumors in children: current insights. <i>European Journal of Pediatrics</i> , 2023, 182, 4833-4850.	1.3	1
800	Recent Advances in Pediatric Medulloblastoma. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	2.0	1
817	Evolution of neurosurgical advances and nuances in medulloblastoma therapy. <i>Child's Nervous System</i> , 0, , .	0.6	0
828	Heterogeneity and tumoral origin of medulloblastoma in the single-cell era. <i>Oncogene</i> , 2024, 43, 839-850.	2.6	0